4CPS-239 Therapeutic drug monitoring of gentamicin in neonates

Background and importancePeak (maximum plasma concentration)/MIC >8–15 is a pharmacokinetic (PK)/pharmacodynamic (PD) parameter that best correlates with the effectiveness of aminoglycosides. A peak between 8 and 15 mg/L is necessary to achieve this. In neonates, doses of 3–5 mg/kg/day for the fi...

Full description

Saved in:
Bibliographic Details
Published in:European journal of hospital pharmacy. Science and practice 2021-03, Vol.28 (Suppl 1), p.A34-A35
Main Authors: Ortega-Garcia, MP, Zaragozá- González, M, Pérez-Villalón, P, Gil-Gómez, I, Moya-Gil Ana, A, Gómez-Bayona, E, Laguía-Sánchez, R, Blasco-Segura, P
Format: Article
Language:English
Subjects:
Conflicts of interest
Drug dosages
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and importancePeak (maximum plasma concentration)/MIC >8–15 is a pharmacokinetic (PK)/pharmacodynamic (PD) parameter that best correlates with the effectiveness of aminoglycosides. A peak between 8 and 15 mg/L is necessary to achieve this. In neonates, doses of 3–5 mg/kg/day for the first week and 7.5 mg/kg/day from the second to the fourth week of life are recommended.Aim and objectivesTo evaluate the degree of adequacy of the initial dose with current recommendations and whether therapeutic drug monitoring (TDM) allows optimisation of treatment.Material and methodsA retrospective study was conducted from 1 January 2016 to 29 February 2020, in a general university hospital. Patients 0–35 days old treated with gentamicin and with plasma concentrations (Cp) were reviewed. The descriptive analysis was performed with the SPSSV.24 programme.Results47 patients with a median age of 3 days (0–33) were studied, 33 male. 26 (55.3%) were
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2021-eahpconf.71